Clinical TrialJun 29, 2026, 08:44 AM
Polyrizon Gets IRB Approval for NASARIX™ Clinical Trial
AI Summary
Polyrizon Ltd. announced it has received central Institutional Review Board (IRB) approval from BRANY to commence its first human clinical trial for NASARIX™, an innovative nasal spray designed to block airborne allergens. This approval, granted on June 18, 2026, is a significant regulatory milestone, confirming the study protocol, patient consent forms, and trial materials meet ethical and participant protection requirements. The study will assess the efficacy, safety, and tolerability of NASARIX™ in patients with seasonal allergic rhinitis, comparing it against a saline spray control. The company plans to proceed with site activation and patient enrollment following site-specific IRB approvals.
Key Highlights
- Polyrizon received central IRB approval for its first human clinical trial for NASARIX™.
- Approval granted by BRANY Institutional Review Board on June 18, 2026.
- The study will evaluate NASARIX™ efficacy, safety, and tolerability in seasonal allergic rhinitis patients.
- The approval covers clinical protocol (PL14-CTP-01), consent forms, and trial materials.
- Approval is valid through June 17, 2027, with site-specific approvals still required.
Price Impact
More from PLRZ